CDK4/6 inhibitors: Promising opportunities beyond breast cancer

Joline S.J. Lim; Nicholas C. Turner; Timothy A. Yap

doi:10.1158/2159-8290.CD-16-0563

CDK4/6 inhibitors: Promising opportunities beyond breast cancer

Joline S.J. Lim, Nicholas C. Turner, Timothy A. Yap

Research output: Contribution to journal › Article › peer-review

26 Scopus citations

Abstract

Patnaik and colleagues report on the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of abemaciclib for the treatment of advanced solid cancers, demonstrating antitumor activity in advanced breast cancers as well as glioblastoma, melanoma, non–small cell lung cancer, colorectal cancer, and ovarian cancer. The development of abemaciclib and other CDK4/6 inhibitors should now be fully optimized through the use of novel predictive biomarkers of response and rational combinations.

Original language	English (US)
Pages (from-to)	697-699
Number of pages	3
Journal	Cancer Discovery
Volume	6
Issue number	7
DOIs	https://doi.org/10.1158/2159-8290.CD-16-0563
State	Published - Jul 1 2016
Externally published	Yes

ASJC Scopus subject areas

Oncology

Access to Document

10.1158/2159-8290.CD-16-0563

Cite this

@article{3b866ff98289400f80c801d30cb56cc2,

title = "CDK4/6 inhibitors: Promising opportunities beyond breast cancer",

abstract = "Patnaik and colleagues report on the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of abemaciclib for the treatment of advanced solid cancers, demonstrating antitumor activity in advanced breast cancers as well as glioblastoma, melanoma, non–small cell lung cancer, colorectal cancer, and ovarian cancer. The development of abemaciclib and other CDK4/6 inhibitors should now be fully optimized through the use of novel predictive biomarkers of response and rational combinations.",

author = "Lim, {Joline S.J.} and Turner, {Nicholas C.} and Yap, {Timothy A.}",

year = "2016",

month = jul,

day = "1",

doi = "10.1158/2159-8290.CD-16-0563",

language = "English (US)",

volume = "6",

pages = "697--699",

journal = "Cancer Discovery",

issn = "2159-8274",

publisher = "American Association for Cancer Research Inc.",

number = "7",

}

TY - JOUR

T1 - CDK4/6 inhibitors

T2 - Promising opportunities beyond breast cancer

AU - Lim, Joline S.J.

AU - Turner, Nicholas C.

AU - Yap, Timothy A.

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Patnaik and colleagues report on the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of abemaciclib for the treatment of advanced solid cancers, demonstrating antitumor activity in advanced breast cancers as well as glioblastoma, melanoma, non–small cell lung cancer, colorectal cancer, and ovarian cancer. The development of abemaciclib and other CDK4/6 inhibitors should now be fully optimized through the use of novel predictive biomarkers of response and rational combinations.

AB - Patnaik and colleagues report on the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of abemaciclib for the treatment of advanced solid cancers, demonstrating antitumor activity in advanced breast cancers as well as glioblastoma, melanoma, non–small cell lung cancer, colorectal cancer, and ovarian cancer. The development of abemaciclib and other CDK4/6 inhibitors should now be fully optimized through the use of novel predictive biomarkers of response and rational combinations.

UR - http://www.scopus.com/inward/record.url?scp=84977509957&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84977509957&partnerID=8YFLogxK

U2 - 10.1158/2159-8290.CD-16-0563

DO - 10.1158/2159-8290.CD-16-0563

M3 - Article

C2 - 27371575

AN - SCOPUS:84977509957

SN - 2159-8274

VL - 6

SP - 697

EP - 699

JO - Cancer Discovery

JF - Cancer Discovery

IS - 7

ER -

CDK4/6 inhibitors: Promising opportunities beyond breast cancer

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this